Improved Glycemic Control With Intraperitoneal Versus Subcutaneous Insulin in Type 1 Diabetes

• DOI: 10.2337/dc08-2340
• Publication Date: 2009-05-09T01:30:41Z
• Authors: Susan J. Logtenberg; Nanne Kleefstra; Sebastiaan T. Hou...; Klaas H. Groenier; Reinold O. Gans; Evert van Ballegooie; Henk J. Bilo
• Keywords: Insulin pump; Crossover study

OBJECTIVE Continuous intraperitoneal insulin infusion (CIPII) with an implantable pump has been available for the past 25 years. CIPII, its specific pharmacodynamic properties, may be a viable treatment alternative to improve glycemic control in patients type 1 diabetes whom other therapies have failed. There few studies which CIPII was compared subcutaneous poor control. RESEARCH DESIGN AND METHODS In open-label, prospective, crossover, randomized, 16-month study, effects of and were 24 patients. The primary outcome measure incidence hypoglycemia. Secondary measures A1C, glucose profile, including time euglycemia, as measured by continuous monitoring. RESULTS grade hypoglycemic events 4.0 +/- 2.6 per week 3.5 2.3 during (P = 0.13). absolute mean difference A1C -0.76% (95% CI -1.41 -0.11) 0.03). Baseline spent euglycemia 45.2 12.6% increased 10.9% (4.6-17.3) (absolute value; P 0.003). no differences occurrence rate severe events, daily use, or BMI. No catheter malfunction observed study. CONCLUSIONS Although we did not observe significant reduction improved achieved use CIPII. We saw 0.8% decrease 11% increase euglycemia.